IGHV3-21 gene frequency in a Swedish cohort of patients with newly diagnosed chronic lymphocytic leukemia

Nicola Cahill; Lesley-Ann Sutton; Mattias Jansson; Fiona Murray; Larry Mansouri; Rebeqa Gunnarsson; Fergus Ryan; Karin E Smedby; Christian Geisler; Gunnar Juliusson; Richard Rosenquist

doi:10.1016/j.clml.2012.01.009

IGHV3-21 gene frequency in a Swedish cohort of patients with newly diagnosed chronic lymphocytic leukemia

Nicola Cahill, Lesley-Ann Sutton, Mattias Jansson, Fiona Murray, Larry Mansouri, Rebeqa Gunnarsson, Fergus Ryan, Karin E Smedby, Christian Geisler, Gunnar Juliusson, Richard Rosenquist

Institut for Klinisk Medicin

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

11 Citationer (Scopus)

Abstract

The IGHV3-21 gene has been shown to be overrepresented in Scandinavian patients with chronic lymphocytic leukemia (CLL). By investigating a population-based cohort of 337 Swedish patients with CLL, a lower (6.5%)IGHV3-21 frequency was determined relative to our previous hospital-based studies (10.1%-12.7%), yet this frequency remained higher compared to other Western CLL cohorts (2.6%-4.1%). Furthermore, we confirmed the poor outcome for patients with IGHV3-21 to be independent of mutational and stereotypy status.

Originalsprog	Engelsk
Tidsskrift	Clinical Lymphoma, Myeloma & Leukemia
Vol/bind	12
Udgave nummer	3
Sider (fra-til)	201-6
Antal sider	6
ISSN	2152-2650
DOI	https://doi.org/10.1016/j.clml.2012.01.009
Status	Udgivet - 2012

Adgang til dokumentet

10.1016/j.clml.2012.01.009

Citationsformater

@article{89422f4ed4b143e78174be13478bd658,

title = "IGHV3-21 gene frequency in a Swedish cohort of patients with newly diagnosed chronic lymphocytic leukemia",

abstract = "The IGHV3-21 gene has been shown to be overrepresented in Scandinavian patients with chronic lymphocytic leukemia (CLL). By investigating a population-based cohort of 337 Swedish patients with CLL, a lower (6.5%)IGHV3-21 frequency was determined relative to our previous hospital-based studies (10.1%-12.7%), yet this frequency remained higher compared to other Western CLL cohorts (2.6%-4.1%). Furthermore, we confirmed the poor outcome for patients with IGHV3-21 to be independent of mutational and stereotypy status.",

author = "Nicola Cahill and Lesley-Ann Sutton and Mattias Jansson and Fiona Murray and Larry Mansouri and Rebeqa Gunnarsson and Fergus Ryan and Smedby, {Karin E} and Christian Geisler and Gunnar Juliusson and Richard Rosenquist",

year = "2012",

doi = "10.1016/j.clml.2012.01.009",

language = "English",

volume = "12",

pages = "201--6",

journal = "Clinical Lymphoma, Myeloma & Leukemia",

issn = "2152-2650",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - IGHV3-21 gene frequency in a Swedish cohort of patients with newly diagnosed chronic lymphocytic leukemia

AU - Cahill, Nicola

AU - Sutton, Lesley-Ann

AU - Jansson, Mattias

AU - Murray, Fiona

AU - Mansouri, Larry

AU - Gunnarsson, Rebeqa

AU - Ryan, Fergus

AU - Smedby, Karin E

AU - Geisler, Christian

AU - Juliusson, Gunnar

AU - Rosenquist, Richard

PY - 2012

Y1 - 2012

N2 - The IGHV3-21 gene has been shown to be overrepresented in Scandinavian patients with chronic lymphocytic leukemia (CLL). By investigating a population-based cohort of 337 Swedish patients with CLL, a lower (6.5%)IGHV3-21 frequency was determined relative to our previous hospital-based studies (10.1%-12.7%), yet this frequency remained higher compared to other Western CLL cohorts (2.6%-4.1%). Furthermore, we confirmed the poor outcome for patients with IGHV3-21 to be independent of mutational and stereotypy status.

AB - The IGHV3-21 gene has been shown to be overrepresented in Scandinavian patients with chronic lymphocytic leukemia (CLL). By investigating a population-based cohort of 337 Swedish patients with CLL, a lower (6.5%)IGHV3-21 frequency was determined relative to our previous hospital-based studies (10.1%-12.7%), yet this frequency remained higher compared to other Western CLL cohorts (2.6%-4.1%). Furthermore, we confirmed the poor outcome for patients with IGHV3-21 to be independent of mutational and stereotypy status.

U2 - 10.1016/j.clml.2012.01.009

DO - 10.1016/j.clml.2012.01.009

M3 - Journal article

C2 - 22464020

SN - 2152-2650

VL - 12

SP - 201

EP - 206

JO - Clinical Lymphoma, Myeloma & Leukemia

JF - Clinical Lymphoma, Myeloma & Leukemia

IS - 3

ER -